Kathy Yi

Kathy Yi, MBA, is the Chief Operating Officer of Affini-T Therapeutics. She has served as a member of Theseus Pharmaceuticals board of directors since June 2021. She served as Chief Financial Officer of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) from June 2019 to September 2021. Previously, she served as Executive Vice President, Chief Financial Officer and Secretary of Sangamo Therapeutics, Inc. Prior to Sangamo Therapeutics, Kathy was Head of Finance at Novartis Pharmaceutical Corporation. She held various financial management positions of increasing seniority at Life Technologies Corp., which was acquired by Thermo Fisher Scientific in 2014, including Finance Leader, Corporate FP&A, Director of Finance, M&A/Corporate Development and Director of Finance and Global Manufacturing Operations. Kathy also held increasing roles of responsibilities in corporate finance at Intel Corporation.

Kathy holds a Bachelor of Science in Chemical Engineering from the University of California at Berkeley and a Master of Business Administration from Columbia Business School.